The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target

Activation of the epithelial-mesenchymal transition process (EMT) by which alveolar cells in human lung tissue undergo differentiation giving rise to a mesenchymal phenotype (fibroblast/miofibroblasts) has been well recognized as a key element in the origin of idiopathic pulmonary fibrosis (IPF). He...

Full description

Bibliographic Details
Main Authors: Ana Galán-Cobo, Elena Arellano-Orden, Rocío Sánchez Silva, José Luis López-Campos, César Gutiérrez Rivera, Lourdes Gómez Izquierdo, Nela Suárez-Luna, María Molina-Molina, José A. Rodríguez Portal, Miriam Echevarría
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-05-01
Series:Frontiers in Molecular Biosciences
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fmolb.2018.00043/full
id doaj-3459f444f4874aba81661aae570b56ac
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Ana Galán-Cobo
Elena Arellano-Orden
Rocío Sánchez Silva
José Luis López-Campos
José Luis López-Campos
César Gutiérrez Rivera
Lourdes Gómez Izquierdo
Nela Suárez-Luna
María Molina-Molina
María Molina-Molina
José A. Rodríguez Portal
Miriam Echevarría
spellingShingle Ana Galán-Cobo
Elena Arellano-Orden
Rocío Sánchez Silva
José Luis López-Campos
José Luis López-Campos
César Gutiérrez Rivera
Lourdes Gómez Izquierdo
Nela Suárez-Luna
María Molina-Molina
María Molina-Molina
José A. Rodríguez Portal
Miriam Echevarría
The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target
Frontiers in Molecular Biosciences
interstitial lung disease (ILD)
fibrosis
sarcoidosis
aquaporins (AQPs)
inflamation
type II pneumocytes
author_facet Ana Galán-Cobo
Elena Arellano-Orden
Rocío Sánchez Silva
José Luis López-Campos
José Luis López-Campos
César Gutiérrez Rivera
Lourdes Gómez Izquierdo
Nela Suárez-Luna
María Molina-Molina
María Molina-Molina
José A. Rodríguez Portal
Miriam Echevarría
author_sort Ana Galán-Cobo
title The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target
title_short The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target
title_full The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target
title_fullStr The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target
title_full_unstemmed The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New Target
title_sort expression of aqp1 is modified in lung of patients with idiopathic pulmonary fibrosis: addressing a possible new target
publisher Frontiers Media S.A.
series Frontiers in Molecular Biosciences
issn 2296-889X
publishDate 2018-05-01
description Activation of the epithelial-mesenchymal transition process (EMT) by which alveolar cells in human lung tissue undergo differentiation giving rise to a mesenchymal phenotype (fibroblast/miofibroblasts) has been well recognized as a key element in the origin of idiopathic pulmonary fibrosis (IPF). Here we analyzed expression of AQP1 in lung biopsies of patients diagnosed with IPF, and compared it to biopsies derived from patients with diverse lung pneumonies, such as hypersensitivity pneumonitis, sarcoidosis or normal lungs. Immunostaining for AQP1 showed a clear increment of AQP1 localized in the alveolar epithelium in biopsies from IPF patients alone. Moreover, to examine the possible participation of AQP1 in the pathophysiology of IPF, we evaluated its role in the pro-fibrotic transformation induced by transforming growth factor (TGF-β) in vitro. Human alveolar epithelial cells (A549), and fibroblasts derived from an IPF patient (LL29), or fibroblasts from healthy normal lung tissue (MRC-5), were treated with TGF-β, and levels of expression of AQP1, as well as those of E-cadherin, vimentin, α-SMA and collagen were analyzed by RT-qPCR, western blot and immunohistochemistry. An increase of AQP1 mRNA and protein after TGF-β treatment (4–72h) was observed either in A549 or IPF fibroblast-LL29 but not in MRC-5 fibroblasts. A gradual reduction of E-cadherin, and increased expression of vimentin, with no changes in α-SMA levels were observed in A549. Whereas in LL29 and MRC-5, TGF-β1 elicited a large production of collagen and α-SMA that was significantly greater in IPF fibroblast-LL29. Changes observed are consistent with activation of EMT by TGF-β, but whether modifications in AQP1 expression are responsible or independent events occurring at the same time is still unknown. Our results suggest that AQP1 plays a role in the pro-fibrotic TGF-β action and contributes to the etiology and pathophysiology of IPF. Understanding AQP1's role will help us comprehend the fate of this disease.
topic interstitial lung disease (ILD)
fibrosis
sarcoidosis
aquaporins (AQPs)
inflamation
type II pneumocytes
url http://journal.frontiersin.org/article/10.3389/fmolb.2018.00043/full
work_keys_str_mv AT anagalancobo theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT elenaarellanoorden theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT rociosanchezsilva theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT joseluislopezcampos theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT joseluislopezcampos theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT cesargutierrezrivera theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT lourdesgomezizquierdo theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT nelasuarezluna theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT mariamolinamolina theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT mariamolinamolina theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT josearodriguezportal theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT miriamechevarria theexpressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT anagalancobo expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT elenaarellanoorden expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT rociosanchezsilva expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT joseluislopezcampos expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT joseluislopezcampos expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT cesargutierrezrivera expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT lourdesgomezizquierdo expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT nelasuarezluna expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT mariamolinamolina expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT mariamolinamolina expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT josearodriguezportal expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
AT miriamechevarria expressionofaqp1ismodifiedinlungofpatientswithidiopathicpulmonaryfibrosisaddressingapossiblenewtarget
_version_ 1724864079744466944
spelling doaj-3459f444f4874aba81661aae570b56ac2020-11-25T02:21:59ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2018-05-01510.3389/fmolb.2018.00043352851The Expression of AQP1 IS Modified in Lung of Patients With Idiopathic Pulmonary Fibrosis: Addressing a Possible New TargetAna Galán-Cobo0Elena Arellano-Orden1Rocío Sánchez Silva2José Luis López-Campos3José Luis López-Campos4César Gutiérrez Rivera5Lourdes Gómez Izquierdo6Nela Suárez-Luna7María Molina-Molina8María Molina-Molina9José A. Rodríguez Portal10Miriam Echevarría11Departamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, SpainDepartamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, SpainDepartamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, SpainUnidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, SpainCentro de Investigación Biomédica en Red sobre Enfermedades Respiratorias (CIBERES), Madrid, SpainUnidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, SpainServicio Anatomía Patológica, HU Virgen del Rocío Sevilla, Seville, SpainDepartamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, SpainCentro de Investigación Biomédica en Red sobre Enfermedades Respiratorias (CIBERES), Madrid, SpainLaboratorio de Neumologia Experimental, Servicio de Neumologia, Institut d'Investigació Biomédica de Bellvitge, Hospital Universitario de Bellvitge, Barcelona, SpainUnidad Médico-Quirúrgica de Enfermedades Respiratorias, Hospital Universitario Virgen del Rocio, Sevilla, SpainDepartamento de Fisiología Médica y Biofísica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, CSIC, Universidad de Sevilla, Sevilla, SpainActivation of the epithelial-mesenchymal transition process (EMT) by which alveolar cells in human lung tissue undergo differentiation giving rise to a mesenchymal phenotype (fibroblast/miofibroblasts) has been well recognized as a key element in the origin of idiopathic pulmonary fibrosis (IPF). Here we analyzed expression of AQP1 in lung biopsies of patients diagnosed with IPF, and compared it to biopsies derived from patients with diverse lung pneumonies, such as hypersensitivity pneumonitis, sarcoidosis or normal lungs. Immunostaining for AQP1 showed a clear increment of AQP1 localized in the alveolar epithelium in biopsies from IPF patients alone. Moreover, to examine the possible participation of AQP1 in the pathophysiology of IPF, we evaluated its role in the pro-fibrotic transformation induced by transforming growth factor (TGF-β) in vitro. Human alveolar epithelial cells (A549), and fibroblasts derived from an IPF patient (LL29), or fibroblasts from healthy normal lung tissue (MRC-5), were treated with TGF-β, and levels of expression of AQP1, as well as those of E-cadherin, vimentin, α-SMA and collagen were analyzed by RT-qPCR, western blot and immunohistochemistry. An increase of AQP1 mRNA and protein after TGF-β treatment (4–72h) was observed either in A549 or IPF fibroblast-LL29 but not in MRC-5 fibroblasts. A gradual reduction of E-cadherin, and increased expression of vimentin, with no changes in α-SMA levels were observed in A549. Whereas in LL29 and MRC-5, TGF-β1 elicited a large production of collagen and α-SMA that was significantly greater in IPF fibroblast-LL29. Changes observed are consistent with activation of EMT by TGF-β, but whether modifications in AQP1 expression are responsible or independent events occurring at the same time is still unknown. Our results suggest that AQP1 plays a role in the pro-fibrotic TGF-β action and contributes to the etiology and pathophysiology of IPF. Understanding AQP1's role will help us comprehend the fate of this disease.http://journal.frontiersin.org/article/10.3389/fmolb.2018.00043/fullinterstitial lung disease (ILD)fibrosissarcoidosisaquaporins (AQPs)inflamationtype II pneumocytes